Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study

References

• Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology. 2011;50(6):1083–90.
   PubMedGoogle Scholar
• Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol, 2010;20(1):46–53.
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.
   PubMed Web of Science ®Google Scholar
• Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–9.
   PubMedGoogle Scholar
• Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21(2):122–33.
   PubMed Web of Science ®Google Scholar
• van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, Krahn M. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res. 2011;63(1):65–78.
   Google Scholar
• Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7):555–69.
   PubMedGoogle Scholar
• Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15(2):340–51.
   PubMedGoogle Scholar
• Hirabayashi Y, Ishii T, Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int. 2010;30(8):1041–48.
   PubMedGoogle Scholar
• Venkiteshwaran A. Tocilizumab. mAbs. 2009;1(5):432–8.
   PubMedGoogle Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987–97.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010;20(6):539–47.
   PubMedGoogle Scholar
• Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011; 21(1):10–5.
   PubMedGoogle Scholar
• Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.
   PubMedGoogle Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580–4.
   PubMedGoogle Scholar
• European league against Rheumatism (EULAR) recommendations for management. Available from http://www.eular.org/index.cfm?framePage = /recommendations_management.cfm. Accessed on September 22, 2014.
   Google Scholar
• Tanaka E, Hoshi D, Igarashi A, Inoue E, Shidara K, Sugimoto N, et al. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod Rheumatol. 2013;23(4):742–51.
   PubMedGoogle Scholar
• Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, Dejonckheere F. Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK. PharmacoEconomics. 2014;32(8):775–87.
   PubMedGoogle Scholar
• Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576–85.
   PubMedGoogle Scholar
• Navarro Sarabia F, Blanco FJ, Alvaro Gracia JM, Garcia Meijide JA, Poveda JL, Rubio-Rodriguez D, Rubio-Terrés C. [Economic evaluation of rheumathoid arthritis monotherapy with tocilizumab and adalimumab]. Rev Esp Salud Publica. 2013;87(4):343–50.
   PubMedGoogle Scholar
• Kostic M, Jovanovic S, Tomovic M, Milenkovic MP, Jankovic SM. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanit Pregl. 2014;71(2):144–8.
   PubMedGoogle Scholar
• Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology. 2003;42(2):326–35.
   PubMedGoogle Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16(2):75–6.
   PubMedGoogle Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–38.
   PubMedGoogle Scholar
• Hushaw LL, Sawaqed R, Sweis G, Reigle J, Gopal A, Brandt D, et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2010;6:143–52.
   PubMed Web of Science ®Google Scholar
• Said C, Coleiro B, Zarb Adami M, Azzopardi LM, Serracino Inglott A. Cost effectiveness of TNF-alpha Inhibitors in rheumatoid arthritis. Int J Inflam. 2013;2013:581409.
   PubMedGoogle Scholar
• Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999;42(2):347–56.
   PubMedGoogle Scholar
• Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2310–9.
   PubMedGoogle Scholar
• Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology. 2005;44(9):1169–75.
   PubMedGoogle Scholar
• Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64(8):1174–9.
   PubMedGoogle Scholar
• Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16(2):77–84.
   PubMedGoogle Scholar
• Price list of DPC/PDPS (Diagnosis Procedure Combination/Per-Diem Payment System). Available from [http://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken12/dl/setumei_15.pdf]. Accessed on July 2012.
   Google Scholar
• Annual Report on the Labour Force Survey. Available from [http://www.stat.go.jp/data/roudou/]. Accessed on July 2012.
   Google Scholar
• Report of Basic Survey on Wage Structure. Available from [http://www.mhlw.go.jp/toukei/itiran/roudou/chingin/kouzou/detail/index.html]. Accessed on July 2012.
   Google Scholar
• Jobanputra P. A clinician's critique of rheumatoid arthritis health economic models. Rheumatology. 2011;50 Suppl 4:iv48–iv52.
   PubMedGoogle Scholar
• Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–37.
   PubMedGoogle Scholar
• A bridged Life Tables for Japan. Available from [http://www.mhlw.go.jp/english/database/db-hw/lifetb10/]. Accessed on July 2012.
   Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39(5):360–7.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.
   PubMed Web of Science ®Google Scholar
• ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis. 2012;71(2): 161–71.
   PubMedGoogle Scholar
• Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum. 2004;51(6):964–73.
   PubMedGoogle Scholar
• Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology. 2004;43(1):62–72.
   PubMedGoogle Scholar
• Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ. 2010;11(1):95–104.
   PubMedGoogle Scholar
• Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008;75(4): 408–15.
   PubMedGoogle Scholar
• Tanaka E, Hoshi D, Igarashi A. Analysis of direct and indirect medical costs for the care of rheumatoid arthritis patients in a large cohort database, IORRA. Ann Rheum Dis. 2011;70:198.
   Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784–8.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. A Cohort Study of Clinical Care in Rheumatoid Arthritis: the IORRA study. Jpn Med Assoc J. 2009;52(1):54–6.
   Google Scholar
• Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008; 67(8):1153–8.
   PubMedGoogle Scholar
• Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol. 2007;34(2):303–10.
   PubMedGoogle Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17(4):283–9.
   PubMedGoogle Scholar
• Nakajima A, Kamitsuji S, Saito A, Tanaka E, Nishimura K, Horikawa N, et al. Disability and patient's appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol. 2006;16(3):151–7.
   PubMedGoogle Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65(12):1661–3.
   PubMedGoogle Scholar
• Yamanaka H. A cohort study of clinical care in rheumatoid arthritis: the IORRA study. Jpn Med Assoc J. 2009;52:54–6.
   Google Scholar
• Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2008;2:75–82.
   PubMedGoogle Scholar
• Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6(2):189–95.
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomized, non-blinded parallel-group Swefot trial. Lancet. 2012;379(9827): 1712–20.
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomized controlled SWEFOT trial. Ann Rheum Dis. 2014;Apr 15. [Epub ahead of print].
   Google Scholar